AEON Biopharma, Inc.

AEON Biopharma, Inc. (ticker: AEON) is a clinical-stage biopharmaceutical company focused on developing proprietary botulinum toxin complex therapeutics for a range of medical and aesthetic conditions. The company went public through a business combination with Priveterra Acquisition Corp, a SPAC sponsored by Priveterra Holdings LLC that completed its IPO in 2021. The filing, an 8-K submitted to the SEC on July 27, 2023, reflects activity tied to the post-merger public company operating in the healthcare and biotechnology sector. AEON trades on a major U.S. exchange following the completion of its de-SPAC transaction. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time SPAC deal data on AEON and hundreds of other transactions.